Mabylon secures €1.46 million to advance MY012 for IBD

The genetically validated inflammasome pathway in Inflammatory Bowel Disease (IBD) offers the opportunity to develop novel drugs beyond the pathways targeted today.

Building on these premises, Mabylon has secured Eurostars funding for ASCEND, a €1.46M collaborative project to advance MY012, a monoclonal antibody targeting extracellular ASC within the inflammasome pathway.

ASCEND brings together an exceptional consortium with Mabylon, Karolinska Institutet (Prof. Villablanca Lab), and Ambiotis, combining human and animal disease models with biomarker development to position MY012 for clinical development as a highly differentiated therapy for IBD.